Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:MSCLF)

0.5065 +0.0097 (+1.95%)
Streaming Delayed Price Updated: 3:57 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 135,853
Open 0.4900
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.4968
Today's Range 0.4878 - 0.5065
52wk Range 0.3774 - 0.9350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Satellos to Participate in December Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire

Performance

YTD
-19.7%
-19.7%
1 Month
+0.6%
+0.6%
3 Month
+15.3%
+15.3%
6 Month
-0.7%
-0.7%
1 Year
-8.0%
-8.0%

More News

Read More
News headline image
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in November Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in Four September Institutional and Retail Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience Shareholders Elect Two New Board Members
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at the CureDuchenne FUTURES National Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in Two April Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports 2024 Financial Results and Highlights Company Progress
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Satellos Bioscience Inc.
Via Business Wire

Frequently Asked Questions

Is MSCLF publicly traded?
Yes, MSCLF is publicly traded.
What exchange does MSCLF trade on?
MSCLF trades on the OTC Traded
What is the ticker symbol for MSCLF?
The ticker symbol for MSCLF is MSCLF on the OTC Traded
What is the current price of MSCLF?
The current price of MSCLF is 0.5065
When was MSCLF last traded?
The last trade of MSCLF was at 11/25/25 03:57 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.